Marisa Wexler, MS,  senior science writer—

Marisa holds a Master of Science in cellular and molecular pathology from the University of Pittsburgh, where she studied novel genetic drivers of ovarian cancer. Her areas of expertise include cancer biology, immunology, and genetics, and she has worked as a science writing and communications intern for the Genetics Society of America.

Articles by Marisa Wexler

New study finds sexual dysfunction is common in scleroderma

Sexual dysfunction is common among people with systemic scleroderma, but is rarely discussed between patients and their doctors, a new study shows. In the study, “Sexual dysfunction and perceptions of rheumatologist engagement on this issue in patients with systemic sclerosis,” the researchers said the reasons for…

EBV infections may affect risk of developing scleroderma: Analysis

Infection with Epstein-Barr virus (EBV), the virus that causes mononucleosis, may increase the risk of developing systemic sclerosis (SSc), according to a new analysis of genetic data. Findings also indicate that SSc is less likely to develop in people who’ve been infected with human immunodeficiency virus (HIV) or SARS-CoV-2, the…

Efzofitimod found safe, well tolerated in study of SSc-ILD

Efzofitimod was found to be generally safe and well tolerated by patients with systemic sclerosis-associated interstitial lung disease (SSc-ILD) in a proof-of-concept Phase 2 study. No treatment-related serious side effects were reported, with efzofitimod showing early signs of efficacy. In addition, the last patient visit has been completed in…

Scleroderma community gears up for awareness month in June

June is Scleroderma Awareness Month, and the scleroderma community is kicking into gear to spread awareness about the rare, chronic disorder. The National Scleroderma Foundation has selected “Stories of Strength” as this year’s theme, encouraging people with scleroderma to share their stories about how the disease has affected…

ALLO-329 gets FDA fast track designation for diffuse scleroderma

The U.S. Food and Drug Administration (FDA) has granted fast track designation to the cell therapy ALLO-329 to treat active refractory (resistant to treatment) diffuse scleroderma, also known as diffuse systemic sclerosis (SSc). The FDA also gave ALLO-329 fast track designation as a potential treatment for two other inflammatory…

2 blood proteins may help detect lung issues in scleroderma patients

Levels of two blood proteins, calcitonin and SOST, may be markers of lung disease in people with scleroderma, a new study shows. “This study indicates that serum calcitonin and SOST levels are promising biomarkers for [scleroderma]-related PAH [pulmonary arterial hypertension] and ILD [interstitial lung disease], respectively,” the researchers wrote, though…

Living with scleroderma can affect your sense of self, women say

Living with scleroderma requires adapting to changes in a woman’s sense of self, but practicing gratitude and accepting change can help patients reclaim themselves, a study aiming for a “grounded theory” of identify management reports. Its scientists said these findings may lay the groundwork for future studies aiming to…

FDA puts cell therapy CABA-201 on fast track for scleroderma

The U.S. Food and Drug Administration (FDA) has granted fast track designation to the cell therapy CABA-201 for organ dysfunction in people with scleroderma. The agency also granted CABA-201 fast track status to reduce disease activity in people with dermatomyositis, another rare disorder that’s marked by muscle weakness and…